Format

Send to

Choose Destination
J Cyst Fibros. 2019 Feb 6. pii: S1569-1993(19)30013-X. doi: 10.1016/j.jcf.2019.01.007. [Epub ahead of print]

Health economic modelling in Cystic Fibrosis: A systematic review.

Author information

1
Norwich Medical School, Norwich Research Park, University of East Anglia, Norwich, Norfolk NR4 7TJ, UK. Electronic address: b.mohindru@uea.ac.uk.
2
Norwich Medical School, Norwich Research Park, University of East Anglia, Norwich, Norfolk NR4 7TJ, UK.
3
Imperial College London, Emmanuel Kaye Building, 1B Manresa Road, London SW3 6LR, UK.
4
Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.
5
The University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK.

Abstract

INTRODUCTION:

Cystic Fibrosis (CF) is a heritable chronic condition. Due to the genetic and progressive nature of CF, a number of interventions are available for the condition. In the United Kingdom (U.K.) average annual cost of CF treatment is between €49,000 to €76,000 (2012) per patient [1]. A review of health economic modelling studies is warranted to provide decision makers and researchers with an in depth understanding of modelling practices in CF and guidance for future research.

METHODS:

Online searches were performed in the 5 databases, studies were included if they were: a) Model based economic evaluation for management of Cystic Fibrosis. Articles were restricted to English language only, but no restriction was applied on publication year.

RESULTS:

Nine studies were reviewed, most were Markov cohort models. Models evaluated pharmaceutical interventions and drug adherence. Modelling structure was consistent across most articles and a range of sources were used to populate the models. Cost and utility data were based on different sources and elicitation methods respectively. The majority of models failed to incorporate significant health events which impact both cost and disease progression.

CONCLUSION:

In our review we observed a lack of, application of European Medicines Agency (EMA) guidelines for clinical trial endpoints, model structure justifications and lastly, health-related quality of life derived utility information around important clinical events. Future work around conceptual modelling of CF progression, utility valuation of significant health events and meeting EMA guidelines for trial reporting is encouraged.

KEYWORDS:

Cost-effectiveness analysis; Cystic Fibrosis; Health Economics; Modelling

PMID:
30738801
DOI:
10.1016/j.jcf.2019.01.007

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center